地舒单抗联合标准或高剂量特立帕肽的骨密度反应:DATA-HD随机对照试验
DATA-HD研究事后分析比较绝经后骨质疏松女性接受地舒单抗联合标准剂量(20μg/日)或高剂量(40μg/日)特立帕肽治疗15个月后,个体骨密度反应率差异。高剂量组在总髋、股骨颈和腰椎达到临床意义骨密度增幅的比例更高,提示高剂量方案可能更快获得骨密度获益。
要点
- 高剂量组总髋aBMD增幅>3%和>6%的比例显著高于标准剂量组。
- 高剂量组股骨颈aBMD增幅>3%的比例显著更高。
- 腰椎增幅>6%和>9%的比例高剂量组显著更高,>3%两组相似。
核心结论
- 与标准剂量方案相比,更多接受高剂量特立帕肽联合地舒单抗治疗的绝经后骨质疏松女性在髋部和脊柱获得具有临床意义的快速骨密度增益。
研究设计与样本
- 单中心、开放标签、随机对照试验(DATA-HD),绝经后骨质疏松女性完成所有研究访视者60例。
- 受试者接受特立帕肽20μg/日(标准剂量)或40μg/日(高剂量)治疗第0至9个月,重叠地舒单抗60mg治疗第3至15个月,总疗程15个月。
临床怎么用
- 对于绝经后骨质疏松女性,地舒单抗联合高剂量特立帕肽可能使更多患者在髋部和脊柱获得具有临床意义的骨密度快速增益。
局限性
- 单中心、开放标签设计,样本量60例,仅纳入完成所有研究访视者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the Denosumab and High-Dose Teriparatide Administration (DATA-HD) study, we reported that 15 months of combined high-dose (HD) teriparatide and denosumab increased mean areal bone mineral density (aBMD) at the hip and spine more than combined denosumab and standard-dose (SD) teriparatide. OBJECTIVE: In the current analysis, we compare the individual rates of aBMD response between the treatment groups. DESIGN: Single-site, open-label, randomized controlled trial in which postmenopausal women received either teriparatide 20-μg daily (SD) or 40-μg daily (HD) given months 0 through 9, overlapped with denosumab 60 mg, given months 3 through 15 (15 months' total duration). The proportion of participants in the SD and HD groups experiencing total hip, femoral neck, and lumbar spine aBMD gains of >3%, >6%, and >9% were compared. PARTICIPANTS: Postmenopausal women with osteoporosis completing all study visits (n = 60). MAIN OUTCOME MEASURE(S): aBMD (dual x-ray absorptiometry). RESULTS: At the end of the 15-month treatment period, a higher proportion of women in the HD group had aBMD increases >3% (83% vs. 58%, P = .037) and >6% (45% vs. 19%, P = .034) at the total hip, and >3% at the femoral neck (86% vs. 63%, P = .044). At the lumbar spine, >3% response rates were similar, whereas the >6% and >9% response rates were greater in the HD group (100% vs. 79%, P = .012 and 93% vs. 59%, P = .003, respectively). CONCLUSION: Compared with the SD regimen, more women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD. These results suggest that this approach may provide unique benefits in the treatment of postmenopausal osteoporosis.
引用
- Ramchand SK, David NL, Leder BZ, et al. Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT. J Clin Endocrinol Metab. 2020. PMID: 31674641. doi:10.1210/clinem/dgz163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。